Respiratory dysfunction following initiation of mirabegron: A case report

Background: Mirabegron, a β3 adrenergic receptor agonist, is FDA approved for treatment of overactive bladder. Approved in 2012 in the US, there have been no reports of any effects of mirabegron on pulmonary function. Case presentation: We report the case of a 65 year old male with a history of Park...

Descripción completa

Detalles Bibliográficos
Autores principales: Malsin, Elizabeth S., Coleman, John M., Wolfe, Lisa F., Lam, Anna P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402286/
https://www.ncbi.nlm.nih.gov/pubmed/30886821
http://dx.doi.org/10.1016/j.rmcr.2019.02.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402286/
https://www.ncbi.nlm.nih.gov/pubmed/30886821
http://dx.doi.org/10.1016/j.rmcr.2019.02.012

Ejemplares similares